Welcome to our dedicated page for Lensar SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENSAR, Inc. filings document operating results and material events for a commercial-stage medical device company focused on robotic laser systems for cataract procedures. Form 8-K reports furnish quarterly and annual earnings releases, including disclosures on ALLY system activity, installed-base trends, and recurring revenue components such as procedure, lease, and service revenue.
The company’s filings also record capital and governance matters, including common stock listed on Nasdaq under LNSR, officer transition disclosures, and material agreements such as the Priority Credit Line Agreement. Amendments to material-event reports provide additional detail on credit-line terms, collateral arrangements, interest-rate mechanics, and default provisions.
LENSAR (NASDAQ:LNSR) filed additional proxy materials for its pending $14 per-share cash merger with Alcon. The supplement answers shareholder demand letters claiming the May 19 definitive proxy omitted material facts, potentially violating Sections 14(a)/20(a). To pre-empt litigation, LENSAR adds disclosures while denying wrongdoing.
Key additions:
- Confirms no discussions of post-merger employment or equity for executives during Feb 21-26 2025 talks.
- Updates Wells Fargo Securities comps: mean EV/2025E revenue 3.9×, median 2.8×; LENSAR traded at 5.2×.
- WFS selects 4.00-5.25× 2025E and 3.00-4.00× 2026E revenue multiples, implying $12.27–$16.51 per share versus $14.00 cash offer and $16.03 discounted amount.
- Expanded precedent-transaction table (4.0×–6.5× LTM revenue).
The board’s recommendation and the July 2 2025 special-meeting timetable are unchanged.